Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

Home | About RECERCAT | Contact

Català | Castellano

All of RECERCAT

By Communities &
Collections By Defense Date By Authors By Titles By Subject

This Collection

By Defense Date By Authors By Titles By Subject

Statistics

View Statistics All RECERCAT

My RECERCAT

Other repositories directory

RECERCAT Home > Sistema de Salut de Catalunya > Vall d'Hebron Institut d'Oncologia – VHIO > Articles científics - VHIO > View document

To access the full text documents, please follow this link: http://hdl.handle.net/11351/5119

dc.contributor	[Pesarrodona M] Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Jauset T, Beaulieu ME] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Peptomyc S.L. Edifici Cellex, Barcelona, Spain. [Díaz-Riascos ZV, Mancilla S, Fernández Y, Abasolo I] CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. CIBBIM-Nanomedicina Àrea de Validació Funcional i Estudis Preclínics, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona Spain. CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Sánchez-Chardi A] Departament de Biologia Evolutiva Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, Barcelona Spain. [Seras-Franzoso J, Baltà-Foix R] CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic,, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Schwartz Jr S] CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Soucek L] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Peptomyc S.L. Edifici Cellex, Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor	Hospital Universitari Vall d'Hebron
dc.contributor.author	Pesarrodona, Mireia
dc.contributor.author	Jauset González, Antoni
dc.contributor.author	Diaz Riascos, Zamira Vanessa
dc.contributor.author	Sánchez-Chardi, Alejandro
dc.contributor.author	Seras Franzoso, Joaquin
dc.contributor.author	Baltà Foix, Ricardo
dc.contributor.author	Mancilla Zamora, Sandra
dc.contributor.author	Fernández Amurgo, Yolanda
dc.contributor.author	Schwartz Riera, Simó
dc.contributor.author	Abasolo Olaortua, Ibane
dc.contributor.author	Beaulieu, Marie-Eve
dc.contributor.author	Soucek, Laura
dc.date	2020-07-29T11:24:49Z
dc.date	2020-07-29T11:24:49Z
dc.date	2019-07-24
dc.identifier	Pesarrodona M, Jauset T, Díaz‐Riascos ZV, Sánchez‐Chardi A, Beaulieu M, Seras‐Franzoso J, et al. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies. Adv Sci. 2019 Jul 24;6(18):1900849.
dc.identifier	2198-3844
dc.identifier	http://hdl.handle.net/11351/5119
dc.identifier	10.1002/advs.201900849
dc.identifier	31559131
dc.identifier	000477715600001
dc.identifier.uri	http://hdl.handle.net/11351/5119
dc.format	application/pdf
dc.language	eng
dc.publisher	Wiley Online Library
dc.relation	Advanced Science;6(18)
dc.relation	https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201900849
dc.relation	info:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F00272
dc.relation	info:eu-repo/grantAgreement/ES/PE2017-2020/PI17%2F02242
dc.relation	info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F01224
dc.rights	Attribution 4.0 International
dc.rights	http://creativecommons.org/licenses/by/4.0/
dc.rights	info:eu-repo/semantics/openAccess
dc.source	Scientia
dc.subject	Proteïnes recombinants
dc.subject	Mama - Càncer
dc.subject	Medicaments antineoplàstics
dc.subject	ANATOMY::Cells::Cellular Structures::Inclusion Bodies
dc.subject	DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject	CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject	ANATOMÍA::células::estructuras celulares::cuerpos de inclusión
dc.subject	ENFERMEDADES::Neoplasias::Neoplasias por Localización::Neoplasias de la Mama
dc.subject	COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.title	Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.description.abstract	Biofabrication; Cancer therapy; Functional amyloids
dc.description.abstract	Biofabricación; Terapia contra el cáncer; Amiloides funcionales
dc.description.abstract	Biofabricació; Teràpia contra el càncer; Amiloides funcionals
dc.description.abstract	Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.
dc.description.abstract	This study has been supported by La Fundacio Marato TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigacion (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS "NANBIOSIS," more specifically by the Protein Production Platform of CIBER-BBN/IBB () and the Biomaterial Processing and Nanostructuring Unit (), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS "NANBIOSIS," specifically by U20/FVPR (). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award

Show simple item record

All of RECERCAT

This Collection

Statistics

My RECERCAT

Related documents

Other documents of the same author